Last reviewed · How we verify

Anagliptin BID Treatment

JW Pharmaceutical · FDA-approved active Small molecule

Anagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the action of incretin hormones to increase insulin secretion and reduce glucagon in response to meals.

Anagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the action of incretin hormones to increase insulin secretion and reduce glucagon in response to meals. Used for Type 2 diabetes mellitus.

At a glance

Generic nameAnagliptin BID Treatment
Also known asSitagliptin QD Treatment
SponsorJW Pharmaceutical
Drug classDPP-4 inhibitor
TargetDipeptidyl peptidase-4 (DPP-4)
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

As a DPP-4 inhibitor, anagliptin prevents the degradation of GLP-1 and GIP, incretin hormones that regulate postprandial glucose levels. By extending the half-life of these hormones, anagliptin enhances glucose-dependent insulin secretion and suppresses glucagon release, thereby lowering blood glucose in patients with type 2 diabetes. The BID (twice-daily) dosing regimen optimizes glycemic control throughout the day.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: